The amino acid PET tracer L3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA), a radiolabeled analog of L-DOPA, is indicated for the molecular imaging of metabolic abnormalities of presynaptic dopamine transporters and L-type amino acid transporters. In clinical neurology, FDOPA-PET assesses the brain’s dopaminergic function for diagnosing Parkinson’s disease (PD) and differentiation between essential tremor and parkinsonian syndromes. In neuro-oncology, FDOPA-PET uptake measures the rate of L-type amino acid transport activity, given that malignant brain tumors are linked to increased protein synthesis and amino acid transport, resulting in higher uptake than normal tissue. FDOPA-PET is increasingly being used to complement MRI in diagnosing and managing patients with brain tumors, especially gliomas.

Original languageEnglish
Title of host publicationHybrid PET/MR Neuroimaging
Subtitle of host publicationA Comprehensive Approach
PublisherSpringer International Publishing
Number of pages15
ISBN (Electronic)9783030823672
ISBN (Print)9783030823665
StatePublished - Jan 1 2021


  • Dopaminergic imaging
  • Gliomas
  • Neuro-oncology imaging
  • Parkinson’s disease


Dive into the research topics of 'FDOPA in Movement Disorders and Neuro-Oncology'. Together they form a unique fingerprint.

Cite this